A unique dataset of Type Ia supernovae being released today could change how cosmologists measure the expansion history of ...

The Galaxy S25 may not be a radical departure from the S24, but it still brings enough upgrades to make it a worthy upgrade. Here's why it deserves a spot in your pocket.

The Anderson transition is a phase transition that occurs in disordered systems, which entails a shift from a diffusive state ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

Royalty Pharma Plc (RPRX) reported its Q4 2024 earnings today, revealing earnings per share (EPS) of $0.3531, falling short of the forecasted $0.9849. The company also reported revenue of $594 million ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...

To precache or to bundle your PSOs, that is the question. Fortunately, Epic has the answer, too.

Bedgear has launched a sale on many of its temperature-regulating pillows and bedding accessories, including a luxury Glacier ...

Netflix, a standout among the FAANG stocks, was a key beneficiary of the post-COVID bull market, delivering exceptional returns. Over the past year, the stock has nearly doubled, driven by robust ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to $550.00. Andrew Fein has given his Buy rating due ...